Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chatbot help african american kidney donors decide with confidence?

NCT ID NCT04910867

Knowledge-focused Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study tests a program that combines an AI chatbot and genetic counseling to help African American living kidney donor candidates understand APOL1 genetic testing. The goal is to reduce uncertainty and improve informed consent about donation. Researchers will enroll about 280 adults at two transplant centers and measure decision-making confidence and satisfaction. The program aims to address cultural concerns and support donors who face a higher risk of kidney disease after donation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A culturally tailored APOL1 genetic testing program that includes an AI chatbot and genetic counseling for living kidney donor candidates
What this could lead to
If successful, this program could become a model for integrating culturally competent genetic testing into transplant care, helping African American donor candidates make more informed decisions about donation.
What could go wrong
This is an early-stage study without a control group, so it may not prove the program's effectiveness. The chatbot and counseling may not fully address cultural concerns or improve decision-making as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

280 people

The number who actually took part.

Started

Sep 2021

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Living kidney donor candidates who identify as African American/Black, Jamaican, Barbadian, Grenadian, Brazilian from Salvador Trinidadian, Panamanian, Honduran, Haitian, Garifunan, Palenque, Guyanese, Dominican, Peruvian, Belizean, and Native American, or state that they have African ancestry or are aware of having biologically-related family with African ancestry * Living kidney donor candidates may be directed or non-directed donors * Adults (ages 18+) * English-speaking * Cognitively intact individuals * All genders Exclusion Criteria: * Individuals who do not identify as African American/Black and are not aware of having any biologically-related family with African ancestry and do not have African ancestry * Only African Americans and people of African ancestry will be included because APOL1 risk variants are predominantly found in African Americans and people who have African ancestry. * Pregnant women cannot be living kidney donors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Apolipoprotein L1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Apolipoprotein L1 Chronic kidney diseases Kidney transplantation

Contacts and locations

Locations

  • Medstar Georgetown Transplant Institute

    Washington D.C., District of Columbia, 20007, United States

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.